Redeye revisits some assumptions related to financing and likelihood of approval following the progr...
SEK 120+7m retrofit order to be delivered in 2025-2035 Covers our '25e-'28e Retrofit assumptions, ~1...
Q4e: 15% organic sales growth y-o-y, 11% adj. EBITA margin Expect a solid Q4, partly on light comps ...
Redeye gives its preview on OssDsign’s Q3 2024 report, due on February 4.
Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations.
Redeye offers a preview of Polygien's Q4 results set to be released on February 13.
The greatest excitement regarding Aspo's Q4 results faded when the company downgraded its full-year ...
We estimate 2024 net profit of DKK 310m, at the upper end of the recently updated 2024 guidance rang...
Inför Q4-rapporten räknar Analysguiden med en svagare efterfrågan, särskilt inom industrisegmentet, ...
Preliminary Q4 sales SEK 8.2m, cash balance SEK 17m '25e-'26e sales and EBIT unchanged, EPS changes ...
Q4 due on 13 February Negative organic growth but +14% adj.
Exposure to fast-growing and non-cyclical infrastructure We forecast 23% EBITA CAGR in '23-'26e, ~40...
Minor estimate changes Contract cancellations to carry negative impact on Q4 Trading at NTM EV/EBITA...
Redeye comments on Freemelt’s preliminary Q4 figures, which came in stronger than expected in terms ...
Redeye updates on EG7 ahead of Q4-results (due 7 February) where we expect continued sequential resu...
Ahead of NoHo's Q4 2024 report, due out 12 February, we tweak our estimates.
Redeye comments on the latest developments from TH1NG, including the temporary replacement of the in...
Mangold uppdaterar sin syn på greentech-bolaget ChargePanel efter det största avtalet i bolagets his...
Redeye provides a comment on today's news from Scandinavian Chemotech, where the company announced t...
Q4e: sales of SEK 42m, adj. EBIT of SEK 11m '24e-'26e sales up by 1-5% Q4 EBIT should be diluted sli...
